PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.49%
Negative EBIT growth while AGEN is at 12.77%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-15.26%
Negative operating income growth while AGEN is at 15.59%. Joel Greenblatt would press for urgent turnaround measures.
-50.43%
Negative net income growth while AGEN stands at 10.88%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-43.14%
Negative EPS growth while AGEN is at 11.19%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-43.14%
Negative diluted EPS growth while AGEN is at 11.19%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
5.01%
Share count expansion well above AGEN's 0.32%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
5.01%
Diluted share count expanding well above AGEN's 0.32%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-30.81%
Negative OCF growth while AGEN is at 14.12%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-30.34%
Negative FCF growth while AGEN is at 12.79%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-52488.47%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-16557.44%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-182.36%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-47013.60%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-7873.57%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-9.65%
Negative 3Y CAGR while AGEN is 18.61%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
20722.38%
10Y equity/share CAGR above 1.5x AGEN's 873.70%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
5960.52%
5Y equity/share CAGR above 1.5x AGEN's 530.04%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
359.30%
3Y equity/share CAGR above 1.5x AGEN's 131.30%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-9.39%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-49.71%
We’re deleveraging while AGEN stands at 3.35%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
10.16%
We increase R&D while AGEN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
23.98%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.